Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Decreases By 38.7%

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 9,500 shares, a decrease of 38.7% from the August 31st total of 15,500 shares. Based on an average daily volume of 8,200 shares, the short-interest ratio is currently 1.2 days.

Adlai Nortye Trading Up 6.6 %

ANL stock opened at $2.10 on Friday. Adlai Nortye has a 1-year low of $1.90 and a 1-year high of $19.30. The business’s 50 day moving average is $2.83 and its 200-day moving average is $6.49.

Institutional Trading of Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. raised its position in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,310 shares of the company’s stock after buying an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned 0.11% of Adlai Nortye worth $362,000 as of its most recent SEC filing. Institutional investors own 35.21% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ANL. Cantor Fitzgerald restated an “overweight” rating on shares of Adlai Nortye in a research note on Thursday, June 20th. HC Wainwright started coverage on shares of Adlai Nortye in a report on Wednesday, September 4th. They set a “buy” rating and a $9.00 price objective for the company.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.